Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,300.51 +53.83 (+1.03%) Dow
39,835.94 +277.83 (+0.70%) Nasdaq
16,727.91 +216.73 (+1.31%) Bitcoin USD
65,658.27 +4,267.02 (+6.95%) CMC Crypto 200
1,378.76 +110.82 (+8.73%)
Cara Therapeutics, Inc. (CARA)
| Previous close | 0.7236 |
| Open | 0.7236 |
| Bid | 0.7499 x 200 |
| Ask | 0.7753 x 100 |
| Day's range | 0.7025 - 0.7900 |
| 52-week range | 0.5000 - 4.4800 |
| Volume | |
| Avg. volume | 584,100 |
| Market cap | 43.244M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Cara Therapeutics Reports First Quarter 2024 Financial Results
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetic
- GlobeNewswire
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at www.CaraTherapeutics.com. Abo
- GlobeNewswire
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT. A webcast of the presentation can be accessed under "Events & Presentations"
